Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-09-17
1992-03-24
Lee, Lester L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 7, 514 89, 514 91, 514 92, 514 94, 514171, 514212, 514218, 5142235, 514249, 514255, 514278, 514318, 514338, 514343, 514409, 514422, 514423, 514616, 514693, A61K 3702, C07K 506
Patent
active
050988891
ABSTRACT:
A method is provided for imhibiting loss of cognitive functon, including memory, which may or may not be associated with Alzheimer's disease, by administering an ACE inhibitor, such as captopril, fosinopril, zofenopril or ceranapril in combination with a drug that acts as serotonin receptors such as zacopride, over a prolonged period of treatment.
REFERENCES:
patent: 4046889 (1977-09-01), Ondetti et al.
patent: 4311697 (1982-01-01), Krapcho
patent: 4311705 (1982-01-01), Ondetti et al.
patent: 4316906 (1982-02-01), Ondetti et al.
patent: 4337201 (1982-06-01), Petrillo, Jr.
patent: 4379146 (1983-04-01), Greenlee et al.
patent: 4381297 (1983-04-01), Karanewsky et al.
patent: 4452790 (1984-06-01), Karanewsky et al.
patent: 4504492 (1985-03-01), Wilkinson et al.
patent: 4602002 (1986-07-01), Patchett et al.
patent: 4931430 (1990-06-01), Sudilovsky et al.
Arregui et al. J. Neurochem. 103:1490-1492 (1982).
Barnes, J. M. et al. "The Effects of Ondansetron, 5-HT.sub.3 Receptor Antagonist, on Cognition in Rodents and Primates", Pharmacol. Biochem. Behav (35; 955-961).
Mann, J. F. E., et al, Clin. Sci., 56:585-589 (1979).
Vollmer, R. R., et al, Europ. J. Pharmacol., 45:117-125 (1977).
Croog, et al, "The effects of Antihypertensive Therapy on the Quality of Life", New England Journal of Medicine, 314:1657-1664 (Jun. 26), 1986.
Sudilovsky et al, "The effects of Zofenopril, Captopril and Methyldopa on Shuttle Avoidance Response Extinction in Rats", Poster Presentation, 15th Congress of the Collegium Internationale Neuro-Psychopharmacologicum, San Juan, Puerto Rico, Dec., 1986.
Sudilovsky et al, "Differential Effects of Captopril, Methyldopa and Propranolol on Cognitive Functioning of Hypertensive Patients," Poster Presentation, 25th Annual Meeting of the American College of Neuropsychopharmacology, Wash., D.C. Dec. '86.
"Angiotensin Converting Enzyme Inhibitors: Animal Experiments Suggest a New Pharmacological Treatment for Alcohol Abuse in Human," G. Spinosa et al, Alcoholism: Clinical and Experimental Research, vol. 12, No. 1, Jan./Feb. 1988, pp. 65-70.
"Alcohol Satiety, Hypertension and the Renin-Angiotensin System," L. A. Grupp, Medical Hypotheses (1987) 24, 11-19 (Longman Group UK Ltd 1987).
Melo, J. C., et al, J. Pharmacol., 193:1-9 (1975).
Morgan, J. M., et al, Science, 196:87-89 (1977).
Koller, M., et al, Neuroscience Letters, 14:71-75 (1979).
Evered, M. D., Europ. J. Pharmacol., 68:443-449 (1980).
Marson, O., et al, Brazil. J. Med. Biol. Res., 14:73-76 (1981).
Scholkens, B. A., et al, Clin. Exper. Hyper.-Theor. Pract., A5:1301-1317 (1983).
Costall et al. (1989), "The effects of ACE inhibitors captopril and SO29,852 in rodent tests of cognition," Pharmacol. Biochem. Behav. 33; 573-579.
Sudilovsky et al, "Captopril Delays Extinction of Conditional Avoidance Response in the Rat," Poster Presentation, 14th Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Florence, Italy, Jun. 1984.
Costall Brenda
Horovitz Zola P.
E. R. Squibb & Sons Inc.
Lee Lester L.
Rodney Burton
LandOfFree
Method for preventing or inhibiting loss of cognitive function e does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing or inhibiting loss of cognitive function e, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing or inhibiting loss of cognitive function e will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2010288